• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Mesenchymal Stem/Stromal Cell-Based Therapy for Heart Failure - What Is the Best Source? 
    •   QMRO Home
    • William Harvey Research Institute
    • Translational Medicine & Therapeutics
    • Mesenchymal Stem/Stromal Cell-Based Therapy for Heart Failure - What Is the Best Source?
    •   QMRO Home
    • William Harvey Research Institute
    • Translational Medicine & Therapeutics
    • Mesenchymal Stem/Stromal Cell-Based Therapy for Heart Failure - What Is the Best Source?
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Mesenchymal Stem/Stromal Cell-Based Therapy for Heart Failure - What Is the Best Source?

    View/Open
    Published version
    Embargoed until: 2100-01-01
    Reason: Publisher archiving policy unknown
    Volume
    82
    Pagination
    2222 - 2232
    Publisher
    Japanese Circulation Society
    DOI
    10.1253/circj.CJ-18-0786
    Journal
    Circ J
    Issue
    9
    Metadata
    Show full item record
    Abstract
    Transplantation of stem/progenitor cells is a promising, emerging treatment for heart failure (HF) in the modern era. Mesenchymal stem/stromal cells (MSCs) are considered as one of the most promising cell sources for this purpose, because of their powerful secretion of reparative factors and immunomodulatory ability. To date, various sources of MSCs have been examined for the treatment of HF in preclinical or clinical studies, including adult tissues (bone marrow and adipose tissue), perinatal tissues (umbilical cord and amnion), and pluripotent stem cells (induced pluripotent stem cells and embryonic stem cells). Adult tissue-derived MSCs have been more extensively examined. Previous clinical trials have suggested the safety and feasibility of these MSCs in HF treatment, but their therapeutic effects remain arguable. Perinatal tissue-derived MSCs have the advantages of removing the necessity of invasiveness biopsy and of mass production. An increasing number of clinical studies (albeit early stage) have been conducted. Pluripotent stem cell-derived MSCs may be another promising source because of their mass-production ability underpinned by their unlimited expansion with consistent quality. However, the risk of tumorigenicity restricts their clinical application. In this review, we summarize the current information available from preclinical and clinical studies, highlighting the advantages and disadvantages of each MSC type. This will provide an insight into consideration of the best MSC source for the treatment of HF.
    Authors
    Kobayashi, K; Suzuki, K
    URI
    https://qmro.qmul.ac.uk/xmlui/handle/123456789/55163
    Collections
    • Translational Medicine & Therapeutics [92]
    Language
    eng
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.